Nocion Therapeutics, Inc.
Biotechnology ResearchMassachusetts, United States11-50 Employees
Nocion Therapeutics is a clinical-stage biopharmaceutical company focused on bringing long-awaited relief to people living with chronic cough, pain, itch, and other conditions caused by overactive sensory nerves. We are developing a new treatment platform made up of targeted molecules designed to act directly on inflamed sensory nerves. By calming these specific nerve signals at their source, our approach aims to deliver longer-lasting, more effective relief, without dulling normal sensation. Our lead clinical program is tapuclainium dry powder for inhalation, a first‑in‑class therapy in development for adults with refractory or unexplained chronic cough (rCC/uCC). These conditions can last for months or even years and affect an estimated 9 million adults in the United States. Many of these individuals have few effective treatment options available today. At Nocion, our goal is straightforward: provide targeted relief for people with chronic, underserved conditions so they can return to speaking, working, sleeping, and living with fewer interruptions. Follow us for updates on our science and clinical progress.
1-888-653-2347 
support@leadiq.com 
